Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 12, 2009, Pages 4629-4634

  Lu, Timothy K ^a,b   Collins, James J ^b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Boston University   (United States)

Author keywords

Antibiotic adjuvants; Antibiotic resistance; Bacterial persistence bacteriophage therapy; Synthetic biology

Indexed keywords

AMPICILLIN; GENTAMICIN; LEXA PROTEIN; OFLOXACIN; OUTER MEMBRANE PROTEIN F; PROTEIN CSRA; PROTEIN DERIVATIVE; PROTEIN SOXR; SOS PROTEIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOPHAGE M13; BACTERIUM MUTANT; BIOENGINEERING; BIOFILM; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; EXPRESSION VECTOR; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DAMAGE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SURVIVAL; ADJUVANT CHEMOTHERAPY; ANIMAL; BACTERIOPHAGE; CYTOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENE REGULATORY NETWORK; GENETIC ENGINEERING; GENETICS; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENE REGULATORY NETWORKS; GENETIC ENGINEERING; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; QUINOLONES; SOS RESPONSE (GENETICS); SURVIVAL ANALYSIS;

EID: 63849290890     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0800442106     Document Type: Article

References (53)

1. Wise R (2004) The relentless rise of resistance? J Antimicrob Chemother 54(2):306-310.
2. Hall-Stoodley L, Costerton JW, Stoodley P (2004) Bacterial biofilms: From the natural environment to infectious diseases. Nature Reviews Microbiology 2(2):95-108.
3. Hall BG (2004) Predicting the evolution of antibiotic resistance genes. Nature Reviews Microbiology 2(5):430-435.
4. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S (2004) Bacterial persistence as a phenotypic switch. Science 305(5690):1622-1625.
5. Lewis K (2007) Persister cells, dormancy and infectious disease. Nature Reviews Microbiology 5(1):48-56.
6. Walsh C (2003) Where will new antibiotics come from? Nature Reviews Microbiology 1(1):65-70.
7. Dwyer DJ, Kohanski MA, Hayete B, Collins JJ (2007) Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Molecular Systems Biol- ogy3:91.
8. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ (2007) A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130(5):797-810.
9. Merril CR, Scholl D, Adhya SL (2003) The prospect for bacteriophage therapy in Western medicine. Nature Reviews Drug Discovery2(6):489 -497.
10. Hagens S, Blasi U (2003) Genetically modified filamentous phage as bactericidal agents: A pilot study. Letters in Applied Microbiology 37(4):318-323.
11. Hagens S, Habel AvAU, von Gabain A, Blasi U (2004) Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 48(10):3817-3822.
12. Westwater C, et al. (2003) Use of genetically engineered phage to deliver antimicrobial agents to bacteria: An alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47(4):1301-1307.
13. Heitman J, Fulford W, Model P (1989) Phage Trojan horses: A conditional expression system for lethal genes. Gene 85(1):193-197.
14. Brüssow H (2005) Phage therapy: The Escherichia coli experience. Microbiology 151(Pt 7):2133-2140.
15. Summers WC (2001) Bacteriophage therapy. Annu Rev Microbiol 55:437-451.
16. Lu TK, Collins JJ (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 104(27):11197-11202.
17. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94(22):12106-12111.
18. Chait R, Craney A, Kishony R (2007) Antibiotic interactions that select against resistance. Nature 446(7136):668-671.
19. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med 10(12 Suppl):S122-S129.
20. Hagens S, Habel A, Bläsi U (2006) Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Microbial Drug Resistance (Larchmont, NY) 12(3):164-168.
21. Miller C, et al. (2004) SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 305(5690):1629-1631.
22. Lewin CS, Howard BM, Ratcliffe NT, Smith JT (1989) 4-Quinolones and the SOS response. Journal of Medical Microbiology 29(2):139-144.
23. Little JW, Harper JE (1979) Identification of the lexA gene product of Escherichia coli K-12. Proc Natl Acad Sci USA 76(12):6147-6151.
24. Cirz RT, et al. (2005) Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol 3(6):e176.
25. Yanisch-Perron C, Vieira J, Messing J (1985) Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33(1):103-119.
26. Walker GC (1984) Mutagenesis and inducible responses to deoxyribonucleic acid damage in Escherichia coli. Microbiol Rev 48(1):60-93.
27. Lutz R, Bujard H (1997) Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. Nucleic Acids Res 25(6):1203-1210.
28. Karlsson F, Malmborg-Hager AC, Albrekt AS, Borrebaeck CA (2005) Genome-wide comparison of phage M13-infected vs. uninfected Escherichia coli. Can J Microbiol51(1):29 -35.
29. Schleif R (1972) Fine-structure deletion map of the Escherichia coliL-arabinose operon. Proc Natl Acad Sci USA 69(11):3479 -3484.
30. Martinez JL, Baquero F (2000) Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 44(7):1771-1777.
31. Hidalgo E, Ding H, Demple B (1997) Redox signal transduction: Mutations shifting [2Fe-2S] centers of the SoxR sensor-regulator to the oxidized form. Cell 88(1):121-129.
32. Hidalgo E, Leautaud V, Demple B (1998) The redox-regulated SoxR protein acts from a single DNAsite as a repressor and an allosteric activator. EMBO J 17(9):2629-2636.
33. Zheng M, Doan B, Schneider TD, Storz G (1999) OxyR and SoxRS regulation of fur. J Bacteriol 181(15):4639-4643.
34. Gaudu P, Weiss B (1996) SoxR, a [2Fe-2S] transcription factor, is active only in its oxidized form. Proc Natl Acad Sci USA 93(19):10094-10098.
35. Jackson DW, et al. (2002) Biofilm formation and dispersal under the influence of the global regulator CsrA of Escherichia coli. J Bacteriol 184(1):290-301.
36. Stewart PS, Costerton JW (2001) Antibiotic resistance of bacteria in biofilms. Lancet 358(9276):135-138.
37. Hirai K, Aoyama H, Irikura T, Iyobe S, Mitsuhashi S (1986) Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother 29(3):535-538.
38. Boratynski J, et al. (2004) Preparation of endotoxin-free bacteriophages. Cellular and Molecular Biology Letters 9(2):253-259.
39. Merril CR, et al. (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 93(8):3188-3192.
40. Andrianantoandro E, Basu S, Karig DK, Weiss R (2006) Synthetic biology: New engineering rules for an emerging discipline. Molecular Systems Biology 2:2006.0028.
41. Hasty J, McMillen D, Collins JJ (2002) Engineered gene circuits. Nature 420:224-230.
42. McDaniel R, Weiss R (2005) Advances in synthetic biology: On the path from prototypes to applications. Curr Opin Biotechnol 16(4):476-483.
43. Chan LY, Kosuri S, Endy D (2005) Refactoring bacteriophage T7. Molecular Systems Biology 1:2005.0018.
44. Guido NJ, et al. (2006) A bottom-up approach to gene regulation. Nature 439:856-860.
45. Deans TL, Cantor CR, Collins JJ (2007) A tunable genetic switch based on RNAi and repressor proteins for regulating gene expression in mammalian cells. Cell 130(2):363-372.
46. Anderson JC, Clarke EJ, Arkin AP, Voigt CA (2006) Environmentally controlled invasion of cancer cells by engineered bacteria. J Mol Biol 355(4):619-627.
47. Loose C, Jensen K, Rigoutsos I, Stephanopoulos G (2006) A linguistic model for the rational design of antimicrobial peptides. Nature 443(7113):867-869.
48. Ro D-K, et al. (2006) Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440(7086):940-943.
49. Hickman-Brenner FW, Stubbs AD, Farmer JJ (1991) Phage typing of Salmonella entertidis in the United States. J Clin Microbiol 29(12):2817-2823.
50. Kohanski MA, Dwyer DJ, Wierzbowski J, Cottarel G, Collins JJ (2008) Mistranslation of membrane proteins and two-component system activation trigger antibiotic mediated cell death. Cell 135(4):679-690.
51. Baker D, et al. (2006) Engineering life: building a fab for biology. Sci Am 294(6):44-51.
52. Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430(6996):242-249.
53. Stewart JB, et al. (2008) Strong purifying selection in transmission of mammalian mitochondrial DNA. PLoS Biol 6(1):e10.